Literature DB >> 10030844

Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators.

J Pugin1, M C Widmer, S Kossodo, C M Liang, A F Suffredini.   

Abstract

Bacterial sepsis is characterized by a systemic inflammatory state, with activation of numerous cell types. Phagocytes participate in this phenomenon by secreting various proinflammatory cytokines and enzymes. Matrix metalloproteinases (MMPs) such as gelatinases are produced by phagocytes and are thought to play an important role in processes of cell transmigration and tissue remodeling. In this work, we show that endotoxin (lipopolysaccharide [LPS]) and other inflammatory mediators, such as tumor necrosis factor (TNF), interleukin-8, and granulocyte colony-stimulating factor, induce a rapid (within 20 min) release of gelatinase-B (MMP-9) zymogen in whole human blood, as determined by gelatin zymography. The polymorphonuclear neutrophil was identified as the cell responsible for this rapid secretion, as a result of the release of preformed enzymes stored in granules. Normal human subjects given LPS intravenously showed a similar pattern of proMMP-9 secretion, with maximum plasma levels reached 1.5 to 3 h after LPS administration (P = 0.0009). Prior administration of TNF receptor:Fc, a potent TNF antagonist, to subjects given LPS, only partially blunted the release of proMMP-9 (P = 0.033). Ibuprofen, a cyclooxygenase inhibitor, did not alter this pattern of release. Increased levels of proMMP-9 and proMMP-2, as well as activated forms of MMP-9, were found in plasma from two patients with gram-negative sepsis. The levels of MMPs paralleled the severity of clinical condition and a marker of the severity of sepsis, plasma procalcitonin. These data indicate that MMPs are released in whole blood in response to various inflammatory mediators and that they could serve as sensitive and early markers for cell activation during the course of bacterial sepsis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030844     DOI: 10.1165/ajrcmb.20.3.3311

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  50 in total

Review 1.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 2.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.

Authors:  Kendra J Greenlee; Zena Werb; Farrah Kheradmand
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 3.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

4.  Differential effects of luminal arginine and glutamine on metalloproteinase production in the postischemic gut.

Authors:  Emily K Robinson; Daniel P Kelly; David W Mercer; Rosemary A Kozar
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 Jul-Aug       Impact factor: 4.016

5.  Kinetics and Role of Plasma Matrix Metalloproteinase-9 Expression in Acute Lung Injury and the Acute Respiratory Distress Syndrome.

Authors:  Albert T Hsu; Christopher D Barrett; George M DeBusk; Christian D Ellson; Shiva Gautam; Daniel S Talmor; Diana C Gallagher; Michael B Yaffe
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

6.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Evidence of inflammatory cell involvement in brain arteriovenous malformations.

Authors:  Yongmei Chen; Wei Zhu; Andrew W Bollen; Michael T Lawton; Nicholas M Barbaro; Christopher F Dowd; Tomoki Hashimoto; Guo-Yuan Yang; William L Young
Journal:  Neurosurgery       Date:  2008-06       Impact factor: 4.654

8.  Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis.

Authors:  Fiia P Gäddnäs; Meeri M Sutinen; Marjo Koskela; Taina Tervahartiala; Timo Sorsa; Tuula A Salo; Jouko J Laurila; Vesa Koivukangas; Tero I Ala-Kokko; Aarne Oikarinen
Journal:  Crit Care       Date:  2010-03-31       Impact factor: 9.097

9.  Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.

Authors:  Leonardo Lorente; María M Martín; Lorenzo Labarta; César Díaz; Jordi Solé-Violán; José Blanquer; Josune Orbe; José A Rodríguez; Alejandro Jiménez; Juan M Borreguero-León; Felipe Belmonte; Juan C Medina; Maria C Llimiñana; José M Ferrer-Agüero; José Ferreres; María L Mora; Santiago Lubillo; Manuel Sánchez; Ysamar Barrios; Antonio Sierra; José A Páramo
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

10.  Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?

Authors:  Ursula Hoffmann; Martina Brueckmann; Martin Borggrefe
Journal:  Crit Care       Date:  2009-12-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.